Martin GP - Search Results

1

Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.

Larhrib H, Martin GP, Prime D, Marriott C. Larhrib H, et al. Among authors: martin gp. Eur J Pharm Sci. 2003 Jul;19(4):211-21. doi: 10.1016/s0928-0987(03)00105-2. Eur J Pharm Sci. 2003. PMID: 12885385

2

The influence of carrier and drug morphology on drug delivery from dry powder formulations.

Larhrib H, Martin GP, Marriott C, Prime D. Larhrib H, et al. Among authors: martin gp. Int J Pharm. 2003 May 12;257(1-2):283-96. doi: 10.1016/s0378-5173(03)00156-x. Int J Pharm. 2003. PMID: 12711183

3

Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations.

Zeng XM, MacRitchie HB, Marriott C, Martin GP. Zeng XM, et al. Among authors: martin gp. Pharm Res. 2006 Sep;23(9):2200-9. doi: 10.1007/s11095-006-9055-9. Epub 2006 Aug 10. Pharm Res. 2006. PMID: 16900411

4

Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.

Marriott C, MacRitchie HB, Zeng XM, Martin GP. Marriott C, et al. Among authors: martin gp. Int J Pharm. 2006 Dec 1;326(1-2):39-49. doi: 10.1016/j.ijpharm.2006.07.021. Epub 2006 Jul 16. Int J Pharm. 2006. PMID: 16942848

5

Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.

Zeng XM, MacRitchie HB, Marriott C, Martin GP. Zeng XM, et al. Among authors: martin gp. Int J Pharm. 2007 Mar 21;333(1-2):45-55. doi: 10.1016/j.ijpharm.2006.09.048. Epub 2006 Oct 1. Int J Pharm. 2007. PMID: 17064863

6

Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.

Martin GP, Marriott C, Zeng XM. Martin GP, et al. Pharm Res. 2007 Feb;24(2):361-9. doi: 10.1007/s11095-006-9156-5. Epub 2006 Dec 20. Pharm Res. 2007. PMID: 17177114 Clinical Trial.

7

Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.

Murnane D, Martin GP, Marriott C. Murnane D, et al. Among authors: martin gp. J Pharm Sci. 2009 Feb;98(2):503-15. doi: 10.1002/jps.21450. J Pharm Sci. 2009. PMID: 18506819

8

Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.

Murnane D, Martin GP, Marriott C. Murnane D, et al. Among authors: martin gp. Pharm Res. 2008 Oct;25(10):2283-91. doi: 10.1007/s11095-008-9622-3. Epub 2008 May 29. Pharm Res. 2008. PMID: 18509598

9

Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.

Taki M, Marriott C, Zeng XM, Martin GP. Taki M, et al. Among authors: martin gp. Int J Pharm. 2010 Mar 30;388(1-2):40-51. doi: 10.1016/j.ijpharm.2009.12.031. Epub 2009 Dec 21. Int J Pharm. 2010. PMID: 20026261

10

The 'stage-by-stage' deposition of drugs from commercial single-active and combination dry powder inhaler formulations.

Taki M, Ahmed S, Marriott C, Zeng XM, Martin GP. Taki M, et al. Among authors: martin gp. Eur J Pharm Sci. 2011 Jul 17;43(4):225-35. doi: 10.1016/j.ejps.2011.04.014. Epub 2011 Apr 28. Eur J Pharm Sci. 2011. PMID: 21549837

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

318 results

Search Page

Filters